Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 934261, 11 pages
http://dx.doi.org/10.1155/2014/934261
Review Article

Recent Concepts of Ovarian Carcinogenesis: Type I and Type II

Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin, Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan

Received 29 January 2014; Accepted 31 March 2014; Published 23 April 2014

Academic Editor: Daisuke Aoki

Copyright © 2014 Masafumi Koshiyama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Siegel, E. Ward, O. Brawley, and A. Jemal, “Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths,” CA: Cancer Journal for Clinicians, vol. 61, no. 4, pp. 212–236, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. S. C. Mok, J. Kwong, W. R. Welch et al., “Etiology and pathogenesis of epithelial ovarian cancer,” Disease Markers, vol. 23, no. 5-6, pp. 367–376, 2007. View at Google Scholar · View at Scopus
  4. C. N. Landen Jr., M. J. Birrer, and A. K. Sood, “Early events in the pathogenesis of epithelial ovarian cancer,” Journal of Clinical Oncology, vol. 26, no. 6, pp. 995–1005, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Tortolero-Luna and M. F. Mitchell, “The epidemiology of ovarian cancer,” Journal of Cellular Biochemistry, vol. 59, no. 23, pp. 200–207, 1995. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Ricciardelli and M. K. Oehler, “Diverse molecular pathways in ovarian cancer and their clinical significance,” Maturitas, vol. 62, no. 3, pp. 270–275, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Schildkraut, P. J. Schwingl, E. Bastos, A. Evanoff, C. Hughes, and J. P. Curtin, “Epithelial ovarian cancer risk among women with polycystic ovary syndrome,” Obstetrics and Gynecology, vol. 88, no. 4, part 1, pp. 554–559, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Komatsu, I. Konishi, M. Mandai et al., “Peritoneal papillary serous carcinoma arising in an infertile woman during ovulation-induction therapy: immunohistochemical expression of LH/hCG receptors,” Gynecologic Oncology, vol. 56, no. 3, pp. 470–474, 1995. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Kobayashi, C. Monma, K. Nanbu, I. Konishi, N. Sagawa, and T. Mori, “Case report: rapid growth of an ovarian clear cell carcinoma expressing LH/hCG receptor arising from endometriosis during early pregnancy,” Gynecologic Oncology, vol. 62, no. 2, pp. 309–313, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Kuroda, M. Mandai, I. Konishi et al., “Human ovarian surface epithelial (OSE) cells express LH/hCG receptors, and hCG inhibits apoptosis of OSE cells via up-regulation of insulin-like growth factor-1,” International Journal of Cancer, vol. 91, no. 3, pp. 309–315, 2001. View at Publisher · View at Google Scholar
  11. M. Mandai, I. Konishi, H. Kuroda, and S. Fujii, “LH/hCG action and development of ovarian cancer—a short review on biological and clinical/epidemiological aspects,” Molecular and Cellular Endocrinology, vol. 269, no. 1-2, pp. 61–64, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. I. M. Shih and R. J. Kurman, “Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis,” The American Journal of Pathology, vol. 164, no. 5, pp. 1511–1518, 2004. View at Google Scholar · View at Scopus
  13. R. J. Kurman and I. M. Shih, “Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm,” Human Pathology, vol. 42, no. 7, pp. 918–931, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Koshiyama, I. Konishi, M. Mandai et al., “Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas: correlation with clinicopathology and sex steroid receptor status,” Virchows Archiv, vol. 425, no. 6, pp. 603–609, 1995. View at Google Scholar · View at Scopus
  15. A. D. Santin, F. Zhan, S. Bellone et al., “Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy,” International Journal of Cancer, vol. 112, no. 1, pp. 14–25, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Salani, R. J. Kurman, R. Giuntoli II et al., “Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance,” International Journal of Gynecological Cancer, vol. 18, no. 3, pp. 487–491, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. K. R. Cho and I. M. Shih, “Ovarian cancer,” Annual Review of Pathology, vol. 4, pp. 287–313, 2009. View at Publisher · View at Google Scholar
  18. J. M. J. Piek, P. J. van Diest, R. P. Zweemer et al., “Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer,” Journal of Pathology, vol. 195, no. 4, pp. 451–456, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. J. M. J. Piek, P. Kenemans, and R. H. M. Verheijen, “Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause,” The American Journal of Obstetrics and Gynecology, vol. 191, no. 3, pp. 718–732, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Maeda, S. Ota, Y. Takazawa et al., “Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases,” Virchows Archiv, vol. 457, no. 5, pp. 597–608, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. C. G. Przybycin, R. J. Kurman, B. M. Ronnett, I. Shih, and R. Vang, “Are all pelvic (nonuterine) serous carcinomas of tubal origin?” The American Journal of Surgical Pathology, vol. 34, no. 10, pp. 1407–1416, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Kobayashi, K. Sumimoto, N. Moniwa et al., “Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan,” International Journal of Gynecological Cancer, vol. 17, no. 1, pp. 37–43, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Horiuchi, K. Itoh, M. Shimizu et al., “Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach,” Gynecologic Oncology, vol. 88, no. 3, pp. 309–317, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Nezhat, M. S. Datta, V. Hanson, T. Pejovic, C. Nezhat, and C. Nezhat, “The relationship of endometriosis and ovarian malignancy: a review,” Fertility and Sterility, vol. 90, no. 5, pp. 1559–1570, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. T. van Gorp, F. Amant, P. Neven, I. Vergote, and P. Moerman, “Endometriosis and the development of malignant tumours of the pelvis. A review of literature,” Best Practice and Research: Clinical Obstetrics and Gynaecology, vol. 18, no. 2, pp. 349–371, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Obata, S. J. Morland, R. H. Watson et al., “Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors,” Cancer Research, vol. 58, no. 10, pp. 2095–2097, 1998. View at Google Scholar · View at Scopus
  27. N. Sato, H. Tsunoda, M. Nishida et al., “Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary,” Cancer Research, vol. 60, no. 24, pp. 7052–7056, 2000. View at Google Scholar · View at Scopus
  28. D. M. Dinulescu, T. A. Ince, B. J. Quade, S. A. Shafer, D. Crowley, and T. Jacks, “Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer,” Nature Medicine, vol. 11, no. 1, pp. 63–70, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Mandai, K. Yamaguchi, N. Matsumura, T. Baba, and I. Konishi, “Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management,” International Journal of Clinical Oncology, vol. 14, no. 5, pp. 383–391, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Kato, S. Sasou, and T. Motoyama, “Expression of hepatocyte nuclear factor-1β (HNF-1β) in clear cell tumors and endometriosis of the ovary,” Modern Pathology, vol. 19, no. 1, pp. 83–89, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. K. C. Wiegand, S. P. Shah, O. M. Al-Agha et al., “ARID1A mutations in endometriosis-associated ovarian carcinomas,” The New England Journal of Medicine, vol. 363, no. 16, pp. 1532–1543, 2010. View at Publisher · View at Google Scholar
  32. H. Kajihara, Y. Yamada, H. Shigetomi, Y. Higashiura, and H. Kobayashi, “The dichotomy in the histogenesis of endometriosis-associated ovarian cancer: clear cell-type versus endometrioid-type adenocarcinoma,” International Journal of Gynecological Pathology, vol. 31, no. 4, pp. 304–312, 2012. View at Publisher · View at Google Scholar
  33. T. Okamoto, M. Mandai, N. Mtsumura et al., “Hepatocyte nuclear factor-1β (HNF-1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma,” Molecular Carcinogenesis, 2013. View at Publisher · View at Google Scholar
  34. M. Mandai, N. Matsumura, T. Baba, K. Yamaguchi, J. Hamanishi, and I. Konishi, “Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype,” Cancer Letters, vol. 310, no. 2, pp. 129–133, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Yamaguchi, M. Mandai, S. Toyokuni et al., “Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress,” Clinical Cancer Research, vol. 14, no. 1, pp. 32–40, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Coquelle, F. Toledo, S. Stern, A. Bieth, and M. Debatisse, “A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs,” Molecular Cell, vol. 2, no. 2, pp. 259–265, 1998. View at Google Scholar · View at Scopus
  37. A. X. Meng, F. Jalali, A. Cuddihy et al., “Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells,” Radiotherapy and Oncology, vol. 76, no. 2, pp. 168–176, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. I. T. Gram, A. Lukanova, I. Brill et al., “Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study,” International Journal of Cancer, vol. 130, no. 9, pp. 2204–2210, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. P. J. Mink, M. E. Sherman, and S. S. Devesa, “Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States: results from the SEER program, 1978–1998,” Cancer, vol. 95, no. 11, pp. 2380–2389, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Yamaguchi, M. Mandai, T. Oura et al., “Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes,” Oncogene, vol. 29, no. 12, pp. 1741–1752, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Matsumura, M. Mandai, T. Okamoto et al., “Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling,” Cancer Science, vol. 101, no. 12, pp. 2658–2663, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Koshiyama, N. Matsumura, T. Baba, K. Yamaguchi, Y. Yoshioka, and I. Konishi, “Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib,” Cancer Biology and Therapy, vol. 15, no. 1, pp. 22–25, 2013. View at Publisher · View at Google Scholar
  43. J. Palacios and C. Gamallo, “Mutations in the β-catenin gene (CTNNB1) in endometrioid ovarian carcinomas,” Cancer Research, vol. 58, no. 7, pp. 1344–1347, 1998. View at Google Scholar · View at Scopus
  44. H. Kobayashi, H. Kajiwara, S. Kanayama et al., “Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary. Review,” Oncology Reports, vol. 22, no. 2, pp. 233–240, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. I. G. Campbell, S. E. Russell, D. Y. Choong et al., “Mutation of the PIK3CA gene in ovarian and breast cancer,” Cancer Research, vol. 64, no. 21, pp. 7678–7681, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Willner, K. Wurz, K. H. Allison et al., “Alternate molecular genetic pathways in ovarian carcinomas of common histological types,” Human Pathology, vol. 38, no. 4, pp. 607–613, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Fujita, T. Enomoto, K. Yoshino et al., “Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer,” International Journal of Cancer, vol. 64, no. 6, pp. 361–366, 1995. View at Publisher · View at Google Scholar · View at Scopus
  48. E. Gras, L. Catasus, R. Arguelles et al., “Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors,” Cancer, vol. 92, no. 11, pp. 2829–2836, 2001. View at Publisher · View at Google Scholar
  49. M. Czriker and M. Dockerty, “Mucinous cystadenomas and mucinous cystadenocarcinomas of the ovary, a clinical and pathological study of 355 cases,” Cancer, vol. 7, no. 2, pp. 302–310, 1954. View at Publisher · View at Google Scholar
  50. J. D. Woodruff, L. S. Bie, and R. J. Sherman, “Mucinous tumors of the ovary,” Obstetrics and Gynecology, vol. 16, pp. 699–712, 1960. View at Google Scholar · View at Scopus
  51. R. E. Scully, R. H. Young, P. B. Clement et al., “Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament,” in Atlas of Tumor Pathology, pp. 125–126, Armed Forces Institute of Pathology, Washington, DC, USA, 3rd edition, 1998. View at Google Scholar
  52. K. M. Feeley and M. Wells, “Precursor lesions of ovarian epithelial malignancy,” Histopathology, vol. 38, no. 2, pp. 87–95, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Resta, S. Russo, G. A. Coluci, and J. Prat, “Morphologic precursors of ovarian epithelial tumors,” Obstetrics and Gynecology, vol. 82, no. 2, pp. 181–186, 1993. View at Google Scholar · View at Scopus
  54. H. Salazar, A. K. Godwin, M. B. Daly et al., “Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies,” Journal of the National Cancer Institute, vol. 88, no. 24, pp. 1810–1820, 1996. View at Publisher · View at Google Scholar · View at Scopus
  55. J. L. Rutgers and R. E. Scully, “Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy. A clinicopathologic analysis,” Cancer, vol. 61, no. 2, pp. 340–348, 1988. View at Google Scholar · View at Scopus
  56. D. Lim and E. Oliva, “Precursors and pathogenesis of ovarian carcinoma,” Pathology, vol. 45, no. 3, pp. 229–242, 2013. View at Publisher · View at Google Scholar
  57. K. Nomura and S. Aizawa, “A histogenetic consideration of ovarian mucinous tumors based on an analysis of lesions associated with teratomas or Brenner tumors,” Pathology International, vol. 47, no. 12, pp. 862–865, 1997. View at Google Scholar · View at Scopus
  58. H. D. Hoerl and W. R. Hart, “Primary ovarian mucinous cystadenocarcinomas,” The American Journal of Surgical Pathology, vol. 22, no. 12, pp. 1449–1462, 1998. View at Publisher · View at Google Scholar · View at Scopus
  59. K. R. Lee and R. E. Scully, “Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with ‘pseudomyxoma peritonei’,” The American Journal of Surgical Pathology, vol. 24, no. 11, pp. 1447–1464, 2000. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Pejovic, N. Bürki, K. Odunsi et al., “Well-differentiated mucinous carcinoma of the ovary and a coexisting brenner tumor both exhibit amplification of 12q14-21 by comparative genomic hybridization,” Gynecologic Oncology, vol. 74, no. 1, pp. 134–137, 1999. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Koshiyama, I. Konishi, M. Yoshida et al., “Transitional cell carcinoma of the fallopian tube: a light and electron microscopic study,” International Journal of Gynecological Pathology, vol. 13, no. 2, pp. 175–180, 1994. View at Google Scholar · View at Scopus
  62. J. D. Seidman and F. Khedmati, “Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with walthard cell nests: a study of 120 tumors,” Archives of Pathology and Laboratory Medicine, vol. 132, no. 11, pp. 1753–1760, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Enomoto, C. M. Weghorst, M. Inoue, O. Tanizawa, and J. M. Rice, “K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary,” The American Journal of Pathology, vol. 139, no. 4, pp. 777–785, 1991. View at Google Scholar · View at Scopus
  64. Y. Ichikawa, M. Nishida, H. Suzuki et al., “Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors,” Cancer Research, vol. 54, no. 1, pp. 33–35, 1994. View at Google Scholar · View at Scopus
  65. R. F. Caduff, S. M. Svoboda-Newman, A. W. Ferguson, C. M. Johnston, and T. S. Frank, “Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors,” The American Journal of Surgical Pathology, vol. 23, no. 3, pp. 323–328, 1999. View at Publisher · View at Google Scholar · View at Scopus
  66. M. L. Gemignani, A. C. Schlaerth, F. Bogomolniy et al., “Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma,” Gynecologic Oncology, vol. 90, no. 2, pp. 378–381, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. S. C. Mok, D. A. Bell, R. C. Knapp et al., “Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy,” Cancer Research, vol. 53, no. 7, pp. 1489–1492, 1993. View at Google Scholar · View at Scopus
  68. M. Mandai, I. Konishi, H. Kuroda et al., “Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology,” Human Pathology, vol. 29, no. 1, pp. 34–40, 1998. View at Publisher · View at Google Scholar · View at Scopus
  69. B. M. Ronnett, C. M. Zahn, R. J. Kurman, M. E. Kass, P. H. Sugarbaker, and B. M. Shmookler, “Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis and relationship to ‘pseudomyxoma peritonei’,” The American Journal of Surgical Pathology, vol. 19, no. 12, pp. 1390–1408, 1995. View at Google Scholar · View at Scopus
  70. C. Guerrieri, B. Franlund, and B. Boeryd, “Expression of cytokeratin 7 in simultaneous mucinous tumors of the ovary and appendix,” Modern Pathology, vol. 8, no. 5, pp. 573–576, 1995. View at Google Scholar · View at Scopus
  71. P. Tenti, A. Aguzzi, C. Riva et al., “Ovarian mucinous tumors frequently express markers of gastric, intestinal, and pancreatobiliary epithelial cells,” Cancer, vol. 69, no. 8, pp. 2131–2142, 1992. View at Google Scholar · View at Scopus
  72. I. M. Rodriguez, J. A. Irving, and J. Prat, “Endocervical-like mucinous borderline tumors of the ovary: a clinicopathologic analysis of 31 cases,” The American Journal of Surgical Pathology, vol. 28, no. 10, pp. 1311–1318, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. K. R. Lee and M. R. Nucci, “Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: a clinicopathologic analysis of four cases of an uncommon variant associated with endometriosis,” International Journal of Gynecological Pathology, vol. 22, no. 1, pp. 42–51, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. P. Jha, M. K. Ranson, S. N. Nguyen, and D. Yach, “Estimates of global and regional smoking prevalence in 1995, by age and sex,” The American Journal of Public Health, vol. 92, no. 6, pp. 1002–1006, 2002. View at Google Scholar · View at Scopus
  75. S. J. Jordan, D. C. Whiteman, D. M. Purdie, A. C. Green, and P. M. Webb, “Does smoking increase risk of ovarian cancer? A systematic review,” Gynecologic Oncology, vol. 103, no. 3, pp. 1122–1129, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. V. Benito, A. Lubrano, O. Arencibia et al., “Serous and mucinous borderline ovarian tumors: are there real differences between these two entities?” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 153, no. 2, pp. 188–192, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. J. D. Seidman and R. J. Kurman, “Subclassification of serous borderline tumors of the ovary into benign and malignant types: a clinicopathologic study of 65 advanced stage cases,” The American Journal of Surgical Pathology, vol. 20, no. 11, pp. 1331–1345, 1996. View at Publisher · View at Google Scholar · View at Scopus
  78. R. J. Kurman, K. Visvanathan, R. Roden, T. C. Wu, and I. Shih, “Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis,” The American Journal of Obstetrics and Gynecology, vol. 198, no. 4, pp. 351–356, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. R. Vang, I. Shih, and R. J. Kurman, “Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems,” Advances in Anatomic Pathology, vol. 16, no. 5, pp. 267–282, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. W. G. McCluggage, “The pathology of and controversial aspects of ovarian borderline tumours,” Current Opinion in Oncology, vol. 22, no. 5, pp. 462–472, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. G. Singer, R. Oldt III, Y. Cohen et al., “Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma,” Journal of the National Cancer Institute, vol. 95, no. 6, pp. 484–486, 2003. View at Google Scholar · View at Scopus
  82. C. J. Haas, J. Diebold, A. Hirschmann, H. Rohrbach, and U. Löhrs, “In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential,” Virchows Archiv, vol. 434, no. 2, pp. 117–120, 1999. View at Publisher · View at Google Scholar · View at Scopus
  83. N. L. Seiben, P. Macropoulos, G. M. Roemen et al., “In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours,” Journal of Pathology, vol. 202, no. 3, pp. 336–340, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. D. Mayr, A. Hirschmann, U. Löhrs, and J. Diebold, “KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants,” Gynecologic Oncology, vol. 103, no. 3, pp. 883–887, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. C.-L. Ho, R. J. Kurman, R. Dehari, T. Wang, and I. Shih, “Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors,” Cancer Research, vol. 64, no. 19, pp. 6915–6918, 2004. View at Publisher · View at Google Scholar · View at Scopus
  86. G. Singer, R. Stöhr, L. Cope et al., “Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation,” The American Journal of Surgical Pathology, vol. 29, no. 2, pp. 218–224, 2005. View at Publisher · View at Google Scholar · View at Scopus
  87. R. Dehari, R. J. Kurman, S. Logani, and I. Shih, “The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis,” The American Journal of Surgical Pathology, vol. 31, no. 7, pp. 1007–1012, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Pradhan, B. Davidson, C. G. Tropé, H. E. Danielsen, V. M. Abeler, and B. Risberg, “Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas-an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications,” Virchows Archiv, vol. 454, no. 6, pp. 677–683, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. K.-T. Kuo, B. Guan, Y. Feng et al., “Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas,” Cancer Research, vol. 69, no. 9, pp. 4036–4042, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Jones, T.-L. Wang, R. J. Kurman et al., “Low-grade serous carcinomas of the ovary contain very few point mutations,” Journal of Pathology, vol. 226, no. 3, pp. 413–420, 2012. View at Publisher · View at Google Scholar · View at Scopus
  91. J. Boyd, B. Luo, S. Peri et al., “Whole exome sequence analysis of serous borderline tumors of the ovary,” Gynecologic Oncology, vol. 130, no. 3, pp. 560–564, 2013. View at Publisher · View at Google Scholar
  92. The Cancer Genome Atlas Network, “Integrated genomic analyses of ovarian carcinoma,” Nature, vol. 474, no. 7353, pp. 609–615, 2011. View at Google Scholar
  93. S. C. Lauchlan, “The secondary Mullerian system,” Obstetrical and Gynecological Survey, vol. 27, no. 3, pp. 133–146, 1972. View at Publisher · View at Google Scholar
  94. L. Dubeau, “The cell of origin of ovarian epithelial tumours,” The Lancet Oncology, vol. 9, no. 12, pp. 1191–1197, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. M. M. Altaras, R. Jaffe, M. Corduba, M. Holtzinger, and C. Bahary, “Primary paraovarian cystadenocarcinoma: clinical and management aspects and literature review,” Gynecologic Oncology, vol. 38, no. 2, pp. 268–272, 1990. View at Publisher · View at Google Scholar · View at Scopus
  96. A. L. de Areia, C. Frutuoso, N. Amaral, I. Dias, and C. De Oliveira, “Paraovarian tumor of borderline malignancy—a case report,” International Journal of Gynecological Cancer, vol. 14, no. 4, pp. 680–682, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. R. J. Kurman, R. Vang, J. Junge, C. G. Hannibal, S. K. Kjaer, and I. Shih, “Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis,” The American Journal of Surgical Pathology, vol. 35, no. 11, pp. 1605–1614, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. J. Li, N. Abushahin, S. Pang et al., “Tubal origin of “ovarian” low-grade serous carcinoma,” Modern Pathology, vol. 24, no. 11, pp. 1488–1499, 2011. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Christie and M. K. Oehler, “Molecular pathology of epithelial ovarian cancer,” Journal of the British Menopause Society, vol. 12, no. 2, pp. 57–63, 2006. View at Publisher · View at Google Scholar · View at Scopus
  100. B. C. Powell, E. Kenley, L. M. Chen et al., “Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy,” Journal of Clinical Oncology, vol. 23, no. 1, pp. 127–132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Finch, P. Shaw, B. Rosen, J. Murphy, S. A. Narod, and T. J. Colgan, “Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers,” Gynecologic Oncology, vol. 100, no. 1, pp. 58–64, 2006. View at Publisher · View at Google Scholar · View at Scopus
  102. D. W. Kindelberger, Y. Lee, A. Miron et al., “Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship,” The American Journal of Surgical Pathology, vol. 31, no. 2, pp. 161–169, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. M. J. Callahan, C. P. Crum, F. Medeiros et al., “Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction,” Journal of Clinical Oncology, vol. 25, no. 25, pp. 3985–3990, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. A. K. Folkins, E. A. Jarboe, A. Saleemuddin et al., “A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations,” Gynecologic Oncology, vol. 109, no. 2, pp. 168–173, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. J. M. J. Piek, R. H. M. Verheijen, P. Kenemans, L. F. Massuger, H. Bulten, and P. J. van Diest, “BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis,” Gynecologic Oncology, vol. 90, no. 2, p. 491, 2003. View at Publisher · View at Google Scholar · View at Scopus
  106. E. Y. Chen, K. Mehra, M. Mehrad et al., “Secretory cell outgrowth, PAX2 and serous carcinogenesis in the fallopian tube,” Journal of Pathology, vol. 222, no. 1, pp. 110–116, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. G. Chene, J. Dauplat, N. Radosevic-Robin, A. Cayre, and F. Penault-Llorca, “Tu-be or not tu-be: that is the question… about serous ovarian carcinogenesis,” Critical Reviews in Oncology/Hematology, vol. 88, no. 1, pp. 134–143, 2013. View at Publisher · View at Google Scholar
  108. C. S. Tung, S. C. Mok, Y. T. Tsang et al., “PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas,” Modern Pathology, vol. 22, no. 9, pp. 1243–1250, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. M. H. Roh, Y. Yassin, A. Miron et al., “High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression,” Modern Pathology, vol. 23, no. 10, pp. 1316–1324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  110. J. T. Rabban, S. McAlhany, M. F. Lerwill, J. P. Grenert, and C. J. Zaloudek, “PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma,” The American Journal of Surgical Pathology, vol. 34, no. 2, pp. 137–146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. K. Visvanathan, A. L. Gross, R. J. Kurman, R. Vang, and I. Shih, “Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics,” Journal of Oncology, vol. 2010, Article ID 126295, 9 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  112. M. L. Carcangiu, P. Radice, S. Manoukian et al., “Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers,” International Journal of Gynecological Pathology, vol. 23, no. 1, pp. 35–40, 2004. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Mehrad, G. Ning, E. Y. Chen, K. K. Mehra, and C. P. Crum, “A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube,” Advances in Anatomic Pathology, vol. 17, no. 5, pp. 293–302, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. E. A. Jarboe, A. K. Folkins, R. Drapkin, T. A. Ince, E. S. Agoston, and C. P. Crum, “Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective,” Histopathology, vol. 53, no. 2, pp. 127–138, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. S. Salvador, A. Rempel, R. A. Soslow, B. Gilks, D. Huntsman, and D. Miller, “Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma,” Gynecologic Oncology, vol. 110, no. 3, pp. 408–417, 2008. View at Publisher · View at Google Scholar · View at Scopus
  116. J. D. Seidman, A. Yemelyanova, R. J. Zaino, and R. J. Kurman, “The fallopian tube-peritoneal junction: a potential site of carcinogenesis,” International Journal of Gynecological Pathology, vol. 30, no. 1, pp. 4–11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  117. E. Kuhn, A. Meeker, T. L. Wang, A. S. Sehdev, R. J. Kurman, and I. Shih, “Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis,” The American Journal of Surgical Pathology, vol. 34, no. 6, pp. 829–836, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. V. G. Gorgoulis, L. F. Vassiliou, P. Karakaidos et al., “Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions,” Nature, vol. 434, no. 7035, pp. 907–913, 2005. View at Publisher · View at Google Scholar · View at Scopus
  119. G. Chene, K. Rahimi, A. M. Mes-Masson, and D. Provencher, “Surgical implications of the potential new tubal pathway for ovarian carcinogenesis,” Journal of Minimally Invasive Gynecology, vol. 20, no. 2, pp. 153–159, 2013. View at Publisher · View at Google Scholar
  120. D. A. Bell and R. E. Scully, “Early de novo ovarian carcinoma: a study of fourteen cases,” Cancer, vol. 73, no. 7, pp. 1859–1864, 1994. View at Google Scholar · View at Scopus
  121. A. Flesken-Nikitin, C. I. Hwang, C. Y. Cheng, T. V. Michurina, G. Enikolopov, and A. Y. Nikitin, “Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche,” Nature, vol. 495, no. 7440, pp. 241–245, 2013. View at Publisher · View at Google Scholar